🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 02/09/2009 | 36,86 | 37,00 | 35,79 | 35,85 | -2,77% | 3,28% | 1.412.500 |
| 01/09/2009 | 37,17 | 38,25 | 36,57 | 36,87 | -1,44% | 4,52% | 1.531.900 |
| 31/08/2009 | 36,94 | 37,45 | 36,48 | 37,41 | +0,19% | 2,63% | 1.717.500 |
| 28/08/2009 | 37,40 | 37,64 | 36,82 | 37,34 | -0,08% | 2,19% | 802.200 |
| 27/08/2009 | 36,87 | 37,40 | 36,15 | 37,37 | +1,66% | 3,39% | 1.470.400 |
| 26/08/2009 | 36,32 | 37,05 | 36,32 | 36,76 | +0,05% | 2,01% | 1.057.400 |
| 25/08/2009 | 36,73 | 37,02 | 36,47 | 36,74 | -0,19% | 1,50% | 1.246.500 |
| 24/08/2009 | 37,15 | 37,15 | 36,40 | 36,81 | -0,94% | 2,02% | 917.600 |
| 21/08/2009 | 36,46 | 37,29 | 36,07 | 37,16 | +2,31% | 3,35% | 1.630.300 |
| 20/08/2009 | 36,12 | 36,34 | 35,77 | 36,32 | +0,64% | 1,58% | 913.500 |
| 19/08/2009 | 34,31 | 36,09 | 34,26 | 36,09 | +4,43% | 5,33% | 1.893.800 |
| 18/08/2009 | 33,82 | 34,60 | 33,19 | 34,56 | +2,37% | 4,17% | 1.527.300 |
| 17/08/2009 | 33,82 | 34,00 | 33,50 | 33,76 | -1,63% | 1,48% | 1.369.400 |
| 14/08/2009 | 34,33 | 34,87 | 33,83 | 34,32 | -0,52% | 3,03% | 983.600 |
| 13/08/2009 | 34,11 | 34,78 | 33,91 | 34,50 | +1,50% | 2,55% | 1.329.500 |
| 12/08/2009 | 33,78 | 34,59 | 33,61 | 33,99 | +0,50% | 2,90% | 1.273.000 |
| 11/08/2009 | 34,32 | 34,95 | 33,70 | 33,82 | -2,03% | 3,64% | 1.326.400 |
| 10/08/2009 | 34,58 | 34,89 | 34,33 | 34,52 | -0,92% | 1,62% | 1.343.400 |
| 07/08/2009 | 35,23 | 35,90 | 34,61 | 34,84 | -0,20% | 3,66% | 1.556.200 |
| 06/08/2009 | 36,58 | 36,79 | 34,56 | 34,91 | -5,52% | 6,10% | 2.712.500 |
| 05/08/2009 | 37,80 | 37,98 | 36,76 | 36,95 | -2,12% | 3,23% | 2.252.700 |
| 04/08/2009 | 36,39 | 38,31 | 36,18 | 37,75 | +3,48% | 5,85% | 2.752.300 |
| 03/08/2009 | 36,26 | 36,50 | 35,81 | 36,48 | +1,31% | 1,90% | 1.032.500 |
| 31/07/2009 | 36,17 | 36,67 | 35,69 | 36,01 | -0,22% | 2,71% | 927.700 |
| 30/07/2009 | 36,59 | 36,74 | 35,89 | 36,09 | -0,39% | 2,32% | 1.258.000 |
| 29/07/2009 | 36,01 | 36,98 | 35,93 | 36,23 | +0,39% | 2,92% | 1.183.400 |
| 28/07/2009 | 35,85 | 36,12 | 35,47 | 36,09 | +0,45% | 1,81% | 981.700 |
| 27/07/2009 | 35,57 | 36,00 | 35,45 | 35,93 | -0,11% | 1,55% | 743.800 |
| 24/07/2009 | 35,19 | 35,98 | 35,01 | 35,97 | +1,35% | 2,76% | 915.700 |
| 23/07/2009 | 33,77 | 35,94 | 33,43 | 35,49 | +4,23% | 7,43% | 1.688.900 |